To assess the impact of the SARS-CoV-2 booster dose on the immune response against COVID-19, we conducted a cross-sectional study in the Casablanca-Settat region of Morocco. The study included 2,802 participants from 16 provinces, all of whom had received three doses of a SARS-CoV-2 vaccine. IgG antibodies targeting the S1 RBD subunit of the SARS-CoV-2 spike protein were quantified using the SARS-CoV-2 IgG II Quant assay and measured on the Abbott Architect i2000SR instrument.
View Article and Find Full Text PDFDelivering COVID-19 vaccines with 4-6 weeks shelf life remains one of Africa's most pressing challenges. The Africa Centres for Disease Control and Prevention (Africa CDC) leadership recognised that COVID-19 vaccines donated to many African countries were at risk of expiry considering the short shelf life on delivery in the Member States and slow vaccine uptake rates. Thus, a streamlined rapid response system, the urgent support mechanism, was developed to assist countries accelerate COVID-19 vaccine uptake.
View Article and Find Full Text PDFAssessing the prevalence of SARS-CoV-2 IgG positivity through population-based serological surveys is crucial for monitoring COVID-19 vaccination efforts. In this study, we evaluated SARS-CoV-2 IgG positivity within a provincial cohort to understand the magnitude of the humoral response against the SARS-CoV-2 vaccine and to inform evidence-based public health decisions. A community-based cross-sectional seroprevalence study was conducted, involving 10,669 participants who received various vaccines (two doses for BBIBP-CorV/Sinopharm, Covishield vaccine, and Pfizer/BioNTech, and one dose for Johnson & Johnson's Janssen COVID-19 vaccine).
View Article and Find Full Text PDFInadequate supply of PPE, vaccines, and diagnostics during the COVID-19 pandemic in Africa created an opportunity to promote local manufacturing. Authors describe Africa CDC's contributions and highlight strategies for strengthening the pandemic response.
View Article and Find Full Text PDF